Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
On the other hand, the SURPASS-5 study showed tirzepatide at doses up to 15 mg weekly reduced HbA1c by up to 2.34% and produced weight loss of up to 10.5 kg over 40 weeks, outperforming placebo by a wide margin (NCBI Bookshelf)
doi: 10.2337/dc19-0749 Summary Keywords obesity, oral semaglutide, GLP-1 receptor agonist, efficacy, safety, real-world evidence, weight loss Citation Krajnc M, Kuhar N and Koceva A (2025) Oral semaglutide for the treatment of obesity: a retrospective real-world study
Z Naturforsch C J Biosci
Albuquerque, A., Cappello, C., Stirrup, O
US$ 29.65
US$ 20.02
US$ 22.40
US$ 25.37
US$ 25.69
US$ 27.78
